OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
OKYO Pharma Limited announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, showcasing its lead drug candidate OK-101 for treating inflammatory dry eye disease and neuropathic corneal pain. OK-101, a novel long-acting lipid-conjugated peptide, has shown promising results in a Phase 2 trial for dry eye disease, and the company is preparing to initiate a Phase 2 trial for treating corneal pain. OKYO Pharma, a NASDAQ-listed biopharmaceutical company, focuses on developing innovative therapies for ocular diseases with significant unmet medical needs.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
